Pasithea Therapeutics Corp.
KTTA
NASDAQ·Healthcare·Biotechnology·Mkt cap $19.4M
$0.58
▼ -0.07%
P/E
—
Mkt Cap
$19.4M
52-Wk Range
$0.28–$2.06
52-Week Range
$0.28 - $2.06
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 24.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Integrated research and clinical services model
- Specialized expertise in ketamine therapeutics and psychiatric treatment
- Early-mover advantage in ketamine-assisted therapy clinic operations
- Proprietary drug discovery pipeline for neuropsychiatric disorders
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Expanding acceptance and clinical validation of ketamine therapy for treatment-resistant depression
Value
Valuation data unavailable
Momentum
Stable
+0.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying KTTA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 14, 2026
Reported EPS of -$0.16 vs -$0.16 consensus (0.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
0.0%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Apr 20, 2026
vs Industry
How KTTA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.